Castle Biosciences works with all insurance providers, including Medicare, Medicaid, commercial insurers, and the VA, to secure coverage and payment for the DecisionDx-SCC test. Castle will submit insurance claims and manage the insurance billing process on behalf of patients. The company also sponsors an industry-leading Patient Assistance ...MyPath Melanoma has over 35,000 clinically resulted cases and 9 publications including validation to outcomes. DiffDx-Melanoma offers a neural network, artificial intelligence-designed algorithm with a low rate of intermediate results. The test was validated in cutaneous melanocytic lesions to accurately differentiate between benign and ...Castle Biosciences is a molecular diagnostics company that provides tumor-specific information for improved treatment decisions and patient outcomes.Castle Biosciences (CSTL 1.43%) stock was absolutely crushing it on Friday, with shares skyrocketing 54.4% as of 11:47 a.m. ET. The huge gain came after Novitas, a regional Medicare administrative ...Castle Biosciences has, to date, processed all Castle test orders for U.S.-based physicians regardless of the patient’s ability to pay. Castle Biosciences works with all insurance providers, including Medicare, commercial insurers, and the VA, to secure payment coverage for tests. Castle will submit insurance claims and manage the insurance ...Enhanced Metastatic Risk Assessment in Cutaneous Squamous Cell Carcinoma with the 40-Gene Expression Profile Test: An Interview with the Lead Author of DecisionDx-SCC’s Validation Study. Speaker: Sherrif F. Ibrahim, MD, PhD., Assistant Professor, Department of Dermatology, University of Rochester Medical Center.Castle Biosciences, Inc. is a commercial-stage dermatological cancer company, which engages in the provision of genomic information for physicians and patients. The firm offers DecisionDx-Melanoma ...You can download a order form and sample report for any of our tests via the test menu on the right side of this page. The test report is typically delivered within 5 days from specimen receipt at our CLIA-certified, CAP-accredited laboratory. Castle Biosciences is a molecular diagnostics company that provides tumor-specific information for improved treatment decisions and patient outcomes.MyPath Melanoma has over 35,000 clinically resulted cases and 9 publications including validation to outcomes. DiffDx-Melanoma offers a neural network, artificial intelligence-designed algorithm with a low rate of intermediate results. The test was validated in cutaneous melanocytic lesions to accurately differentiate between benign and ...Castle Biosciences is improving health through our innovative tests that guide patient care. For the diseases that our portfolio of tests cover, we believe the traditional approach to developing a treatment plan for cancers and other diseases using clinical and pathology factors alone is inadequate and can be improved by incorporating the ...Castle Biosciences, Inc., CLIA# 03D2096304 3737 N. 7th Street, Suite 160, Phoenix, AZ 85014 Version ò. ì X ì 0 ó/1 õ ©201 õ Tel: (866) 788-9007 Fax: (866) ï î õ- î î î ð Castle ID: u5013-13456 Page 1 of 2 FINAL REPORT Patient: Gerald Hightower Type of Specimen: Fresh Frozen FNAB Sex: Male Specimen ID: N/ACastle Biosciences (CSTL 1.43%) stock was absolutely crushing it on Friday, with shares skyrocketing 54.4% as of 11:47 a.m. ET. The huge gain came after Novitas, a regional Medicare administrative ...Castle Biosciences is improving health through our innovative tests that guide patient care. For the diseases that our portfolio of tests cover, we believe the traditional approach to developing a treatment plan for cancers and other diseases using clinical and pathology factors alone is inadequate and can be improved by incorporating the ...Castle Biosciences has, to date, processed all Castle test orders for U.S.-based physicians regardless of the patient’s ability to pay. Castle Biosciences works with all insurance providers, including Medicare, commercial insurers, and the VA, to secure payment coverage for tests. Castle will submit insurance claims and manage the insurance ...Castle Biosciences, Inc. (NASDAQ:CSTL) Q3 2022 Earnings Conference Call November 2, 2022 4:30 PM ET. Company Participants. Camilla Zuckero - Vice President, Investor Relations and Corporate Affairs.Careers. The culture at Castle Biosciences fosters transparency, teamwork and professional growth—all while contributing to our mission to improve health outcomes for patients with dermatologic cancers using innovative technologies and research. The work of our employees directly influences our reputation and a positive experience at Castle ...Texas - Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, will share new data demonstrating the risk stratification performance of its TissueCypher test in an oral presentation during the Presidential Plenary Session of the 19th ISDE World Congress for Esophageal Diseases, being held Sept. 8-10 in Toronto, Canada.Castle Biosciences (Nasdaq: CSTL) is a leading diagnostics company improving health through innovative tests that guide patient care. The Company aims to transform disease management by keeping ...Web site created using create-react-app. Clinician Ordering Portal Improving health through innovative tests that guide patient careCastle Biosciences to acquire mental health testing co. AltheaDX in deal worth up to $140M. Friendswood-based diagnostics company Castle Biosciences Inc. (Nasdaq: CSTL) will acquire San Diego ...You may contact Castle Biosciences’ transfer agent, Broadridge Corporate Issuer Solutions, Inc. Telephone: 877-830-4936 (toll-free) 720-378-5591 Email:If you're a new customer to Castle Biosciences, please call us when ordering a test. If a returning customer, you can use the requisition form.Castle Biosciences works with all insurance providers, including Medicare, Medicaid, commercial insurers, and the VA, to secure coverage and payment for the DecisionDx-SCC test. Castle will submit insurance claims and manage the insurance billing process on behalf of patients. The company also sponsors an industry-leading Patient Assistance ...Legal Name Castle Biosciences, Inc. Stock Symbol NASDAQ:CSTL. Company Type For Profit. Contact Email [email protected]. Phone Number 602-535-1997. Castle Biosciences is a biotech company that develops and validates diagnostic tests and technologies for the treatment of cancer.Castle Biosciences works with all insurance providers, including Medicare, Medicaid, commercial insurers, and the VA, to secure payment coverage for the DecisionDx-Melanoma Test. Castle will submit insurance claims and manage the insurance billing process on behalf of patients. The company also sponsors an industry-leading Patient Assistance ...Castle Biosciences’ DecisionDx-CM Seq is a 3-gene test that uses next-generation sequencing (NGS) to identify somatic mutations relevant to cutaneous melanoma in melanoma tumor tissue. The test includes hotspot mutations in the genes BRAF, NRAS, and KIT. Mutations in these genes are important to help inform therapy choices for melanoma ...Find a Castle Representative Near You Castle Biosciences field representatives are happy to assist you and discuss how to integrate our tests into your practice. Complete the information below and you'll be contacted by our local representative.Castle Biosciences. Sales (Current Employee) - Friendswood, TX - March 16, 2021. Castle Biosciences is a very culture & mission driven company that genuinely cares for their employees. Working at Castle for almost 5 years now, I can confidently say that I am a valued employee, who is respected as an individual in a company of 240+ employees.Improving health through innovative tests that guide patient care | Castle Biosciences (Nasdaq: CSTL) is a leading diagnostics company focused on transforming disease management by keeping people... Castle Biosciences offers diagnostic tests that provide actionable, tumor-specific information for improved treatment decisions and patient outcomes.fairfax county government center
Castle Biosciences offers diagnostic tests that provide actionable, tumor-specific information for improved treatment decisions and patient outcomes. Skip to content Customer Service: 866-788-9007Castle Biosciences is a molecular diagnostics company that provides tumor-specific information for improved treatment decisions and patient outcomes.You can download a order form and sample report for any of our tests via the test menu on the right side of this page. The test report is typically delivered within 5 days from specimen receipt at our CLIA-certified, CAP-accredited laboratory. Aug 2, 2023 · Castle Biosciences is improving health through our innovative tests that guide patient care. For the diseases that our portfolio of tests cover, we believe the traditional approach to developing a treatment plan for cancers and other diseases using clinical and pathology factors alone is inadequate and can be improved by incorporating the ... Castle Biosciences’ DecisionDx-CM Seq is a 3-gene test that uses next-generation sequencing (NGS) to identify somatic mutations relevant to cutaneous melanoma in melanoma tumor tissue. The test includes hotspot mutations in the genes BRAF, NRAS, and KIT. Mutations in these genes are important to help inform therapy choices for melanoma ...Castle Biosciences, Inc., a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma.DecisionDx-UM is a proprietary GEP (gene expression profile) test that helps healthcare providers predict the risk of metastasis in patients with uveal melanoma. We licensed the intellectual property for DecisionDx-UM from Washington University in St. Louis, Missouri, completed analytical validation, and made the DecisionDx-UM available for ...Castle Biosciences (Nasdaq: CSTL) is a leading diagnostics company improving health through innovative tests that guide patient care. The Company aims to transform disease management by keeping ...service mac mortgage
Castle Biosciences, Incorporated Derek Maetzold, Founder, President, and CEO. Author: Katy Blanchard Created Date: 6/18/2018 11:06:05 AM ...Castle Biosciences is a molecular diagnostics company that provides tumor-specific information for improved treatment decisions and patient outcomes.Castle Biosciences offers diagnostic tests that provide actionable, tumor-specific information for improved treatment decisions and patient outcomes.Past Events. 08/09/2023 12:00 PM ET. Canaccord Genuity 43rd Annual Growth Conference. Webcast. 08/02/2023 04:30 PM ET. Castle Biosciences Q2 2023 Earnings Call. Webcast. 05/03/2023 04:30 PM ET. Castle Biosciences Q1 2023 Earnings Call.About Castle Biosciences. Castle Biosciences is a molecular diagnostics company dedicated to helping patients and their physicians make the best possible decisions about their treatment and follow up care based on the individual molecular signature of their tumor.Castle Biosciences has, to date, processed all Castle test orders for U.S.-based physicians regardless of the patient’s ability to pay. Castle Biosciences works with all insurance providers, including Medicare, commercial insurers, and the VA, to secure payment coverage for tests. Castle will submit insurance claims and manage the insurance ...The average price predicted for Castle Biosciences Inc. (CSTL) by analysts is $33.00, which is $15.4 above the current market price. The public float for CSTL is 25.63M, and at present, short sellers hold a 2.80% of that float. On September 15, 2023, the average trading volume of CSTL was 616.26K shares. Top 5 EV Tech Stocks to Buy for 2023.If you're a new customer to Castle Biosciences, please call us when ordering a test. If a returning customer, you can use the requisition form.Dr. Matthew Goldberg has served as our Medical Director since August 2020. Prior to joining Castle, Dr. Goldberg was an Assistant Professor in Dermatology and Pathology at the Icahn School of Medicine at Mount Sinai in New York and retains his affiliation as an Assistant Clinical Professor of Dermatology. Before joining the Mount Sinai ...Castle Biosciences’ DecisionDx-CM Seq is a 3-gene test that uses next-generation sequencing (NGS) to identify somatic mutations relevant to cutaneous melanoma in melanoma tumor tissue. The test includes hotspot mutations in the genes BRAF, NRAS, and KIT. Mutations in these genes are important to help inform therapy choices for melanoma ...dailyburn
Castle Biosciences, Inc. is a commercial-stage dermatological cancer company, which engages in the provision of genomic information for physicians and patients. The firm offers DecisionDx-Melanoma ...You can download a order form and sample report for any of our tests via the test menu on the right side of this page. The test report is typically delivered within 5 days from specimen receipt at our CLIA-certified, CAP-accredited laboratory. Careers. The culture at Castle Biosciences fosters transparency, teamwork and professional growth—all while contributing to our mission to improve health outcomes for patients with dermatologic cancers using innovative technologies and research. The work of our employees directly influences our reputation and a positive experience at Castle ...Find out what works well at Castle Biosciences, Inc. from the people who know best. Get the inside scoop on jobs, salaries, top office locations, and CEO insights. Compare pay for popular roles and read about the team’s work-life balance. Uncover why Castle Biosciences, Inc. is the best company for you.Castle Biosciences offers DecisionDx-PRAME gene expression profile testing to assess expression of the PRAME (preferentially expressed antigen in melanoma) gene. DecisionDx-PRAME is an optional, additional test that can be run on the same sample as your DecisionDx ® -UM GEP (gene expression profile) test.Castle Biosciences, Inc is an Affirmative Action and Equal Opportunity Employer. All qualified applicants will receive consideration for employment without regard to race, color, religion, sex, sexual orientation, gender identity, national origin, or protected veteran status and will not be discriminated against on the basis of disability.Castle Biosciences works with all insurance providers, including Medicare, Medicaid, commercial insurers, and the VA, to secure coverage and payment for the DecisionDx-SCC test. Castle will submit insurance claims and manage the insurance billing process on behalf of patients. The company also sponsors an industry-leading Patient Assistance ...INVESTIGATION ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Castle Biosciences, Inc. and Encou. June 21, 2023, 10:02 AM UTC. Share this article. CopiedCastle Biosciences, Inc is an Affirmative Action and Equal Opportunity Employer. All qualified applicants will receive consideration for employment without regard to race, color, religion, sex, sexual orientation, gender identity, national origin, or protected veteran status and will not be discriminated against on the basis of disability.At Castle Biosciences, we promise to treat your data with respect and will not share your information with any third party. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below. If you experience any issues with this process, please contact us for further assistance.Castle Biosciences (Nasdaq: CSTL) is a leading diagnostics company improving health through innovative tests that guide patient care. The Company aims to transform disease management by keeping ...If you're a new customer to Castle Biosciences, please call us when ordering a test. If a returning customer, you can use the requisition form.Improving health through innovative tests that guide patient care | Castle Biosciences (Nasdaq: CSTL) is a leading diagnostics company focused on transforming disease management by keeping people...A look at the shareholders of Castle Biosciences, Inc. (NASDAQ:CSTL) can tell us which group is most powerful. The group holding the most number of shares in the company, around 85% to be precise ...Requisition Form Page 2 of 2 FAX THE FOLLOWING DOCUMENTS TOLL FREE AT 1-866-329-2224 (Alternate fax: 602-222-5200) *Order confirmation will be sent to the ordering clinician via fax within 24 hours of receiptAt Castle Biosciences, we promise to treat your data with respect and will not share your information with any third party. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below. If you experience any issues with this process, please contact us for further assistance.Castle Biosciences offers diagnostic tests that provide actionable, tumor-specific information for improved treatment decisions and patient outcomes.ballkanweb
Texas - Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, will share new data demonstrating the risk stratification performance of its TissueCypher test in an oral presentation during the Presidential Plenary Session of the 19th ISDE World Congress for Esophageal Diseases, being held Sept. 8-10 in Toronto, Canada.If you're a new customer to Castle Biosciences, please call us when ordering a test. If a returning customer, you can use the requisition form.DecisionDx-Melanoma is a validated 31-gene expression profile (GEP) test that was developed to identify the risk of recurrence or metastasis including the likelihood of sentinel lymph node positivity for patients with stage I, II, or III melanoma and inform patient management decisions. The DecisionDx-Melanoma test accurately and independently ...Claim your Free Employer Profile. www.castlebiosciences.com. Friendswood, TX. 51 to 200 Employees. Type: Company - Public (CSTL) Revenue: $25 to $100 million (USD) Biotech & Pharmaceuticals.The average price predicted for Castle Biosciences Inc. (CSTL) by analysts is $33.00, which is $15.4 above the current market price. The public float for CSTL is 25.63M, and at present, short sellers hold a 2.80% of that float. On September 15, 2023, the average trading volume of CSTL was 616.26K shares. Top 5 EV Tech Stocks to Buy for 2023.Castle Biosciences is a molecular diagnostics company that provides actionable, tumor-specific information for improved treatment decisions and patient outcomes in dermatologic cancers. We conduct sophisticated studies to develop and validate the accuracy of our tests, which assess specific tumor biology to predict the likelihood of disease ...Dr. Matthew Goldberg has served as our Medical Director since August 2020. Prior to joining Castle, Dr. Goldberg was an Assistant Professor in Dermatology and Pathology at the Icahn School of Medicine at Mount Sinai in New York and retains his affiliation as an Assistant Clinical Professor of Dermatology. Before joining the Mount Sinai ...Castle Biosciences, Inc., CLIA# 03D2096304 3737 N. 7th Street, Suite 160, Phoenix, AZ 85014 Version ò. ì X ì 0 ó/1 õ ©201 õ Tel: (866) 788-9007 Fax: (866) ï î õ- î î î ð Castle ID: u5013-13456 Page 1 of 2 FINAL REPORT Patient: Gerald Hightower Type of Specimen: Fresh Frozen FNAB Sex: Male Specimen ID: N/ALegal Name Castle Biosciences, Inc. Stock Symbol NASDAQ:CSTL. Company Type For Profit. Contact Email [email protected]. Phone Number 602-535-1997. Castle Biosciences is a biotech company that develops and validates diagnostic tests and technologies for the treatment of cancer. Goldberg M, Siegel J, Russell B, et al., A comprehensive diagnostic offering workflow increases the rate of actionable results of the 23- and 35-gene expression profile tests for use as ancillary diagnostic tools for difficult-to-diagnose melanocytic lesions. SKIN The Journal of Cutaneous Medicine 2021; 5 (6), s79.Castle Biosciences’ DecisionDx-CM Seq is a 3-gene test that uses next-generation sequencing (NGS) to identify somatic mutations relevant to cutaneous melanoma in melanoma tumor tissue. The test includes hotspot mutations in the genes BRAF, NRAS, and KIT. Mutations in these genes are important to help inform therapy choices for melanoma ...Hm. Got a letter from my insurer saying the denial of claim was reversed on appeal. I was aware Castle Biosciences was appealing, but did not expect they would succeed. (Castle was not going to collect from me anyway.) ”Upon review of the documentation submitted, the request is approved. The DecisionDx-Melanoma signature indeed may be an ...Castle Biosciences (Nasdaq: CSTL) is a leading diagnostics company improving health through innovative tests that guide patient care. The Company aims to transform disease management by keeping ...The average price predicted for Castle Biosciences Inc. (CSTL) by analysts is $33.00, which is $15.4 above the current market price. The public float for CSTL is 25.63M, and at present, short sellers hold a 2.80% of that float. On September 15, 2023, the average trading volume of CSTL was 616.26K shares. Top 5 EV Tech Stocks to Buy for 2023.how to edit a text messageCastle Biosciences is a molecular diagnostics company that provides actionable, tumor-specific information for improved treatment decisions and patient outcomes in dermatologic cancers. We conduct sophisticated studies to develop and validate the accuracy of our tests, which assess specific tumor biology to predict the likelihood of disease ...Castle Biosciences to acquire mental health testing co. AltheaDX in deal worth up to $140M. Friendswood-based diagnostics company Castle Biosciences Inc. (Nasdaq: CSTL) will acquire San Diego ...Castle Biosciences is improving health through our innovative tests that guide patient care. For the diseases that our portfolio of tests cover, we believe the traditional approach to developing a treatment plan for cancers and other diseases using clinical and pathology factors alone is inadequate and can be improved by incorporating the ...Castle Biosciences is a molecular diagnostics company that provides tumor-specific information for improved treatment decisions and patient outcomes.Castle Biosciences is a molecular diagnostics company that provides tumor-specific information for improved treatment decisions and patient outcomes. Improving health through innovative tests that guide patient care | Castle Biosciences (Nasdaq: CSTL) is a leading diagnostics company focused on transforming disease management by keeping people... Castle Biosciences was founded by Derek Maetzold who believed that traditional methods to determine cancer patients’ prognosis could be improved by newly emerging techniques in molecular biology. We continue to focus on transforming disease management in areas of unmet clinical need through the development and marketing of innovative ...Board Chairman. Daniel M. Bradbury has served as a member our board of directors since September 2012, and as chairman of our board of directors since September 2014. Mr. Bradbury is co-founder and Executive Chairman of Equillium, Inc., a publicly traded biotechnology company, where he also served as its CEO from June 2018 until January 2020 ...By Ben Glickman. Shares of Castle Biosciences jumped Friday after the company said it would present data showing its cancer risk tests were effective. The stock rose 33% to $17.63 in pre-market ...You may contact Castle Biosciences’ transfer agent, Broadridge Corporate Issuer Solutions, Inc. Telephone: 877-830-4936 (toll-free) 720-378-5591 Email:You can download a order form and sample report for any of our tests via the test menu on the right side of this page. The test report is typically delivered within 5 days from specimen receipt at our CLIA-certified, CAP-accredited laboratory. CASTLE BIOSCIENCES 2021 ESG REPORT 2 Letter from Our CEO At Castle Biosciences, we are dedicated to applying innovative diagnostics to inform disease management decisions and improve patient outcomes. Our company was founded on the guiding principle of doing the right thing at the right time. And although we are still early in our journey asMyPath Melanoma has over 35,000 clinically resulted cases and 9 publications including validation to outcomes. DiffDx-Melanoma offers a neural network, artificial intelligence-designed algorithm with a low rate of intermediate results. The test was validated in cutaneous melanocytic lesions to accurately differentiate between benign and ...jobfinder
Board Chairman. Daniel M. Bradbury has served as a member our board of directors since September 2012, and as chairman of our board of directors since September 2014. Mr. Bradbury is co-founder and Executive Chairman of Equillium, Inc., a publicly traded biotechnology company, where he also served as its CEO from June 2018 until January 2020 ...Legal Name Castle Biosciences, Inc. Stock Symbol NASDAQ:CSTL. Company Type For Profit. Contact Email [email protected]. Phone Number 602-535-1997. Castle Biosciences is a biotech company that develops and validates diagnostic tests and technologies for the treatment of cancer. DecisionDx-Melanoma has been included in 30 peer-reviewed publications and has been studied in more than 5,700 patient samples. The test has been validated in four archival risk of recurrence studies of 901 patients and six prospective risks of recurrence studies including more than 1,600 patients. Prediction of the likelihood of sentinel lymph ...Castle Biosciences was founded on the guiding principle of doing the right thing at the right time. Our focus on Environmental, Social and Governance (ESG) factors began with this guiding principle in 2008, when we laid the cornerstones of integrity, transparency, collaboration and innovation. The release of our inaugural ESG report marks an ...Castle Biosciences offers diagnostic tests that provide actionable, tumor-specific information for improved treatment decisions and patient outcomes. Skip to content Customer Service: 866-788-9007The average price predicted for Castle Biosciences Inc. (CSTL) by analysts is $33.00, which is $15.4 above the current market price. The public float for CSTL is 25.63M, and at present, short sellers hold a 2.80% of that float. On September 15, 2023, the average trading volume of CSTL was 616.26K shares. Top 5 EV Tech Stocks to Buy for 2023.Board Chairman. Daniel M. Bradbury has served as a member our board of directors since September 2012, and as chairman of our board of directors since September 2014. Mr. Bradbury is co-founder and Executive Chairman of Equillium, Inc., a publicly traded biotechnology company, where he also served as its CEO from June 2018 until January 2020 ...Castle Biosciences (Nasdaq: CSTL) is a leading diagnostics company improving health through innovative tests that guide patient care. The Company aims to transform disease management by keeping ...Castle Biosciences, Inc is a provider established in Phoenix, Arizona operating as a Clinical Medical Laboratory. The NPI number of this provider is 1770734253 and was assigned on October 2008. The practitioner's primary taxonomy code is 291U00000X .joann stock
DecisionDx-Melanoma has been included in 30 peer-reviewed publications and has been studied in more than 5,700 patient samples. The test has been validated in four archival risk of recurrence studies of 901 patients and six prospective risks of recurrence studies including more than 1,600 patients. Prediction of the likelihood of sentinel lymph ...The Castle Biosciences, Inc. stock price fell by -1.35% on the last day (Friday, 1st Sep 2023) from $19.93 to $19.66. During the last trading day the stock fluctuated 3.33% from a day low at $19.53 to a day high of $20.18. The price has risen in 7 of the last 10 days and is up by 11.96% over the past 2 weeks.Castle Biosciences is a company developing and commercializing diagnostic and prognostic tests for dermatologic cancers. It offers products for diagnosing cutaneous melanoma (DecisionDx-Melanoma, DecisionDx DiffDx-Melanoma, and DecisionDx-CMSeq), solutions for the prognosis and diagnosis of uveal melanoma (DecisionDx-UM, DecisionDx-UMSeq, and DecisionDx-PRAME), and a predictor of metastasis ...The average price predicted for Castle Biosciences Inc. (CSTL) by analysts is $33.00, which is $15.4 above the current market price. The public float for CSTL is 25.63M, and at present, short sellers hold a 2.80% of that float. On September 15, 2023, the average trading volume of CSTL was 616.26K shares. Top 5 EV Tech Stocks to Buy for 2023.